dm+d

55867006

Articles

How should medicines be dosed in children who are obese?

28 May 2021Review on how to calculate medicine doses in children who are obese which includes a table on commonly prescribed medicines.

What injections can be given orally or via enteral feeding tubes?

6 November 2020This updated Medicines Q&A is a quick reference summary to different types of enteral feeding tubes, in relation to medication issues. Not all enteral feeding…

Safety in Lactation: Drugs for obstructive airways disease

25 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Bronchodilators Most bronchodilators are considered to…

What are the clinically significant drug interactions with tobacco smoking?

23 March 2020This Medicines Q&A summarises those drug interactions with tobacco smoking that are considered to be most clinically important. Most interactions between drugs and tobacco smoking…

How is an intravenous aminophylline dose converted to an oral aminophylline or theophylline dose?

27 November 2019This updated Medicines Q&A explains how to convert an intravenous aminophylline dose to an oral aminophylline or theophylline dose and includes examples of conversion calculations
Search Articles

Medicine Compliance Aid Stability

Phyllocontin ContinusNapp Pharmaceuticals Ltd

Napp Pharmaceuticals Ltd
Phyllocontin Continus
Tablet m/r, f/c 225mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Product degrades on exposure to air.
29 September 2015

Phyllocontin Continus ForteNapp Pharmaceuticals Ltd

Napp Pharmaceuticals Ltd
Phyllocontin Continus Forte
Tablet m/r, f/c 350mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Product degrades on exposure to air.
29 September 2015

Lactation Safety Information

Salbutamol; Terbutaline
Xanthine bronchodilator - mixture of theophylline and ethylenediamine
Limited published evidence of safety
Irritability and fretful sleep reported in one breastfed infant
Adverse effects potentially more likely in premature and newborn infants [due to slow elimination and low protein binding]
Modified-release products are preferred to parenteral formulations
Avoid feeding for 2 hours after IV dose
Monitor infant for irritability
Used in infants >1 month
29 July 2020